The elaboration of a small molecular weight cytostatic factor by lymphoblastoid lines and activated lymphocytes.
Cohen Mc , Cohen S , Antonia Sj
Lymphokine research 5 ( 4) 301
1
1986
B7-1 gene-modified tumor cell vaccines.
Antonia Sj
Current Opinion in Molecular Therapeutics 1 ( 1) 50
11
1999
Breast Cancer Escape from T Cell Rejection Mediated by Indoleamine 2,3-Dioxygenase
Scott J Antonia , UNIVERSITY OF SOUTH FLORIDA TAMPA
2002
In chronic colitis exacerbation of altered motility induced by the bacterial peptide formyl-Methionyl-Leucyl-Phenylalanine (fMLP) is associated with dysregulation of the immune system
Caroline B Appleyard , Myrella L Cruz , Domenico Coppola , Zellinette Alvarado
The FASEB Journal 22
2008
Adapting to the brave new world of lung cancer treatment.
Mary C Pinder-Schenck , Scott J Antonia
Oncology 27 ( 5) 411
2013
Propelling Immunotherapy Combinations Into the Clinic.
Nishan Tchekmedyian , Jhanelle E Gray , Benjamin C Creelan , Alberto A Chiappori
Oncology 29 ( 12) 990 -1002
10
2015
Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer.
Scott J Antonia
Clinical advances in hematology & oncology 14 ( 8) 616 -618
2
2016
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Marina C Garassino , Luis Paz-Ares , Rina Hui , Corinne Faivre-Finn
Future Oncology 17 ( 10) 1165 -1184
2021
Effective Combination of Cancer Vaccine With Chemotherapy in Patients With Extensive Stage Lung Cancer
Noweeda N Mirza , Scott J Antonia , Ingo Fricke , Alberto Chiappori
Journal of Immunotherapy 28 ( 6) 612 -613
2005
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A Rizvi , Julien Mazières , David Planchard , Thomas E Stinchcombe
The Lancet Oncology 16 ( 3) 257 -265
1,507
2015
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia , José A López-Martin , Johanna Bendell , Patrick A Ott
The Lancet Oncology 17 ( 7) 883 -895
657
2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann , Naiyer A Rizvi , Jonathan W Goldman , Scott N Gettinger
The Lancet Oncology 18 ( 1) 31 -41
519
2017
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio , Arnaud Scherpereel , Luana Calabrò , Joachim Aerts
Lancet Oncology 18 ( 9) 1261 -1273
389
2017
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Scott J Antonia , Hossein Borghaei , Suresh S Ramalingam , Leora Horn
Lancet Oncology 20 ( 10) 1395 -1408
234
2019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Rina Hui , Mustafa Özgüroğlu , Augusto Villegas , Davey Daniel
Lancet Oncology 20 ( 12) 1670 -1680
40
2019
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
Ben C. Creelan , Scott J Antonia , Gerold Bepler , Timothy J. Garrett
OncoImmunology 2 ( 3) e23428
58
2013
A new role for NFκB in immunosurveillance and its implications for cancer immunotherapy
Amer A Beg , Tahira Khan , Scott J Antonia
OncoImmunology 2 ( 10)
3
2013
Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer
Hatem H Soliman , Susan E Minton , Roohi Ismail-Khan , Hyo S Han
Cancer Research 75
3
2015
Cell-based immune therapy for metastatic renal cancer.
Mayer N Fishman , Scott J Antonia
Expert Review of Anticancer Therapy 3 ( 6) 837 -849
4
2003
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.
Alberto A Chiappori , Hatem Soliman , William E Janssen , Scott J Antonia
Expert Opinion on Biological Therapy 10 ( 6) 983 -991
86
2010